Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (10159)	1/27/2004 11:38:47 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Most agreements allow assignment to a successor with a provision that the successor can't compete in the same space. But in this case there really isn't a present competitor for Genasense, so I would expect the partnership to be legally unaffected, with no chance of GNTA getting the program back "for free." I expect Aventis will be trumpeting its pipeline in the next few weeks, so maybe there'll be some favorable mention for some of its biotech partners. Anyone seen a current list of Aventis's partnerships? Peter